(6-237) Cost Effective Analysis of Pembrolizumab 200 mg every 3 weeks, Pembrolizumab 400 mg every 6 weeks, and Placebo as Adjuvant Therapy in Renal Cell Carcinoma
Tuesday, December 9, 2025
10:45 AM - 11:45 AM
Location: Bayside A, Level 1
Pharmacy School: Saint Joseph's University Philadelphia College of Pharmacy Pharmacy School Location: Pennsylvania
Co-Author(s): Madeline Smith, Jesslin Jose, Andrew Peterson
